Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Multiple Myeloma
Interventions: Bortezomib; Drug
Lead sponsor: Boston VA Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 11
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 8 more

Conditions: Pancreatic Adenocarcinoma
Interventions: Electroporation, gemcitabine, nab-paclitaxel; Device · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Bladder Cancer
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 2,133,575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Wilmington, Delaware • Washington D.C., District of Columbia

Conditions: Sickle Cell Disease
Interventions: Propranolol, Placebo; Drug
Lead sponsor: Laura M. De Castro, MD; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: XIAP Deficiency, NLRC4-MAS
Interventions: Tadekinig alfa; Drug
Lead sponsor: AB2 Bio Ltd.; Industry
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: La Jolla, California • Gainsville, Florida • Atlanta, Georgia + 5 more

Conditions: Bladder Cancer
Interventions: Education Intervention, Nutrition Intervention; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Atopic Dermatitis
Interventions: RPT193, Placebo; Drug
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more

Conditions: Immune System Disorder (Healthy Volunteer)
Interventions: Belumosudil mesylate, Placebo; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Knee Osteoarthritis
Interventions: Pure PRP II, PureBMC; Combination Product
Lead sponsor: Andrews Research & Education Foundation; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Gulf Breeze, Florida

Conditions: Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization
Interventions: (MC-1) Pyridoxal-5'-phosphate; Drug
Lead sponsor: Medicure; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Non Small Cell Lung Cancer
Interventions: Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin, Pharmacokinetic sampling - rosuvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550; Procedure · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Premature Ventricular Complex, Ventricular Arrythmia
Interventions: Non Invasive Electroanatomical Mapping; Diagnostic Test
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Mammography, Biopsy, Needle
Interventions: Novel Breast Compression Paddle; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 2 Diabetes Mellitus
Interventions: Counseling, Usual education; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 14
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Tampa, Florida + 10 more

Conditions: Acne Vulgaris
Interventions: Adapalene/benzoyl peroxide gel, 0.1%/2.5%, Cetaphil Acne Regimen; Drug · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Pflugerville, Texas

Conditions: Mechanical Complication of Cardiac Electronic Device
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Saint Paul, Minnesota • Manhasset, New York • Durham, North Carolina + 1 more

Conditions: Cystic Fibrosis
Interventions: Brensocatib, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Gainesville, Florida • Augusta, Georgia • Glenview, Illinois + 10 more

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions: Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more

Conditions: Adverse Drug Event
Interventions: Medcheck message; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alcoholism
Interventions: Acamprosate, Yohimbine, mCPP, Saline; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bone Loss, Prostate Cancer
Interventions: Zoledronic acid, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Breast Cancer Female, Breast Carcinoma
Interventions: Endocrine Therapy Education Program; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Exenatide, Normal saline .2cc subcutaneous injection; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

An Educational Intervention for Patients With Bladder Cancer

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

Bone Marrow Aspirate Compared to Platelet Rich Plasma for Treating Knee Osteoarthritis

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer

Non-Invasive 3D Mapping for Identifying Origin and Preferential Propagation of Ventricular Arrhythmias

Evaluation Of A Novel Breast Compression Paddle For Wire Localization In Mammography

Physical Activity and Participation

A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B

A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris

Multicenter Imaging in Lead Extraction Study

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Preventing Adverse Drug Events With PatientSite

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy

Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women